Arcus Biosciences, Inc. (RCUS) Covered Calls
You can sell covered calls on Arcus Biosciences, Inc. to lower risk and earn monthly income. Born To Sell's covered call screener gives you customized search capabilities across all possible covered calls but here are a couple of examples for RCUS (prices last updated Fri 4:16 PM ET):
| Arcus Biosciences, Inc. (RCUS) Stock Quote | ||||||
|---|---|---|---|---|---|---|
| Last | Change | Bid | Ask | Volume | P/E | Market Cap |
| 15.70 | -0.07 | 15.21 | 16.20 | 923K | - | 0.0 |
| Covered Calls For Arcus Biosciences, Inc. (RCUS) | ||||||
|---|---|---|---|---|---|---|
| Expiration | Strike | Call Bid | Net Debit | Return If Flat |
Annualized Return If Flat |
|
| Dec 20 | 15 | 1.50 | 14.70 | 2.0% | 20.3% | |
| Jan 17 | 15 | 2.35 | 13.85 | 8.3% | 47.3% | |
| Subscribers get access to the full covered call chain, and more features. | ||||||
Want to make money with covered calls? Sign Up For A Free Trial
Extended Business Description
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing cancer therapies in the United States. The company's product pipeline includes, AB928, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 monoclonal antibody that is in Phase Ib clinical trial for monotherapy. It is also developing AB154, an anti-TIGIT monoclonal antibody, which is in Phase 2 development for the treatment of first-line metastatic non-small cell lung cancer in combination with Zimberelimab and AB928; and AB680, small-molecule CD73 inhibitor is in a Phase 1/1b study for the treatment of first-line metastatic pancreatic cancer. Arcus Biosciences, Inc. has a clinical development collaboration agreement with Strata Oncology, Inc. to evaluate Zimberelimab; a collaboration with AstraZeneca to evaluate domvanalimab (AB154), its investigational anti-TIGIT antibody, in combination with Imfinzi (durvalumab) in a registrational Phase 3 clinical trial in patients with unresectable Stage III non-small cell lung cancer; license agreements with Taiho Pharmaceutical Co., Ltd and Abmuno Therapeutics LLC; and strategic relationship with WuXi Biologics to develop anti-CD39 antibody for the treatment of cancer. The company was founded in 2015 and is based in Hayward, California.
| Top 10 Open Interest For Dec 20 Expiration | Top 5 High Yield | |||||
|---|---|---|---|---|---|---|
| 1. | NVDA covered calls | 6. | QQQ covered calls | 1. | SAVA covered calls | |
| 2. | SPY covered calls | 7. | XLF covered calls | 2. | RKLB covered calls | |
| 3. | EEM covered calls | 8. | KWEB covered calls | 3. | LUNR covered calls | |
| 4. | FXI covered calls | 9. | TLT covered calls | 4. | NMRA covered calls | |
| 5. | IWM covered calls | 10. | KRE covered calls | 5. | CRVS covered calls | |
Want more examples? RCMT Covered Calls | RDFN Covered Calls
